Intellia Therape Stock Price, News & Analysis

Intellia Therapeutics (NTLA) announced promising preclinical data supporting the development of NTLA-6001, an allogeneic CAR-T therapy targeting CD30-expressing hematologic cancers. Presenting at the Keystone Symposia, findings showed that their proprietary engineering platform produced immune-evading T cells, crucial for potent tumor responses. The preclinical data indicated NTLA-6001's potential in treating relapsed or refractory classical Hodgkin lymphoma. The candidate is progressing towards IND-enabling activities, reinforcing Intellia’s commitment to innovative genomic therapies.

Intellia Therapeutics (NASDAQ:NTLA) will announce its first quarter 2022 financial results on May 5, 2022, at 8 a.m. ET. The company, a leader in genome editing focused on CRISPR technology, will discuss operational highlights during a conference call. U.S. participants can dial 1-833-316-0545, while international callers should use 1-412-317-5726. A live webcast will also be available. Post-call, a replay will be accessible on Intellia’s website.

Intellia Therapeutics (NASDAQ: NTLA) announced that its investigational T cell receptor (TCR)-T cell therapy, NTLA-5001, has received orphan drug designation from the FDA for treating acute myeloid leukemia (AML). This therapy targets the Wilms’ Tumor 1 (WT1) antigen, prevalent in AML and other cancers. Currently in a Phase 1/2a clinical trial, NTLA-5001 aims to provide new treatment options for patients with recurrent AML. The orphan status supports development incentives, including potential market exclusivity and tax credits.

Intellia Therapeutics (NTLA) has announced the dosing of the first patient with NTLA-5001, an investigational T cell receptor (TCR) therapy aimed at treating acute myeloid leukemia (AML). This CRISPR/Cas9 engineered therapy targets the Wilms' Tumor 1 (WT1) antigen, frequently found in AML and other cancers. The Phase 1/2a study will assess the therapy's safety, efficacy, and anti-tumor activity. The trial has two arms, focusing on AML patients with varying disease burdens. With over 20,000 new AML cases annually in the U.S., NTLA-5001 represents a significant advancement in cancer treatment.

On February 28, 2022, Intellia Therapeutics and Regeneron Pharmaceuticals announced promising interim results from a Phase 1 clinical trial of NTLA-2001 for treating transthyretin amyloidosis (ATTR). The study demonstrated a mean serum TTR reduction of 93% at the highest dose (1.0 mg/kg) by day 28, with durable reductions lasting between two to twelve months. The treatment was generally well tolerated, with mild adverse effects reported. The companies plan to advance the therapy into a dose-expansion cohort in Q1 2022, marking a significant step in CRISPR-based genomic medicine.

Intellia Therapeutics announced promising interim results from a Phase 1 trial of NTLA-2001, aimed at treating transthyretin (ATTR) amyloidosis. A mean serum TTR reduction of 93% was achieved at the 1.0 mg/kg dose by day 28, with durable effects sustained for 2 to 12 months. The treatment was generally well tolerated, with most adverse events mild. NTLA-2001 is the first CRISPR-based therapy administered systemically, marking a significant advancement in genome editing. Intellia plans to initiate a polyneuropathy dose-expansion cohort in Q1 2022 and will host an investor event to discuss these findings.

Intellia Therapeutics (NASDAQ: NTLA) reported its Q4 2021 results, showcasing significant growth and strategic advancements in its CRISPR-based pipeline. The company plans to present additional interim data from its Phase 1 study on NTLA-2001 for ATTR amyloidosis on February 28, 2022. Notably, Intellia announced two new candidates, NTLA-6001 for hematologic cancers and NTLA-2003 for liver-related AATD. With $1.086 billion in cash as of year-end 2021, up from $597.4 million in 2020, Intellia is well-positioned for future developments. Net loss rose to $81.2 million, emphasizing the costs of advancing multiple clinical programs.

Intellia Therapeutics (NASDAQ:NTLA) has announced a lease agreement for a new 140,000-square-foot GMP manufacturing facility in Waltham, Massachusetts, expected to be operational in 2024. This facility will support the production of components for its CRISPR-based investigational therapies, enhancing manufacturing capacity and capability as the company advances its pipeline. Intellia's Chief Technical Officer emphasized the strategic importance of this investment for efficient production, while the Chief Financial Officer noted the benefits of a long-term lease over building a facility.

Intellia Therapeutics (NASDAQ:NTLA) has announced two virtual investor events in February 2022. The first is the Fourth Quarter and Full-Year 2021 Financial Results, scheduled for February 24 at 8:00 a.m. ET. U.S. callers can dial 1-833-316-0545 to join. The second event is an update on interim clinical data for NTLA-2001, set for February 28 at 4:30 p.m. ET, featuring presentations from leading experts. NTLA-2001 aims to treat ATTR amyloidosis using CRISPR technology, potentially allowing for a single-dose treatment option.